CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Transfusion of SARS-CoV-2 Convalescent Plasma.Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug2526 SOC Wiki 1.00
drug2042 PTC299 Wiki 1.00
drug2959 Transfusion of standard Plasma. Wiki 1.00
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.

COVID-19 (Corona Virus Disease 2019) hospitalized patients evolution is marked by the risk of worsening of the respiratory system during the second week of the disease. To date, treatments are currently being evaluated and none of them have shown to be effective in the care of these patients. The use of convalescent plasma is a passive immunotherapy. It has often been used in respiratory virus epidemic situations (during the 1918 or 2009 influenza pandemic, or during SARS-CoV-1 or MERS-CoV pandemic). Effects reported in literature are in favour of a beneficial impact of transfusion of these plasma without serious adverse effects reported. PlasCoSSA is a randomized, controlled, triple-blinded, parallel clinical trial. This study tests the efficacy of convalescent plasma transfusion therapy in the early care of COVID-19 hospitalized patients outside intensive care units.

NCT04372979 COVID-19 Drug: Transfusion of SARS-CoV-2 Convalescent Plasma. Drug: Transfusion of standard Plasma.

Primary Outcomes

Description: Survival time without needs of ventilator, i.e. the time until oxygen supply (patient previously in ambient air), or an increase by more than 6L/min of O2 for more than 24 hours, or the use of non-invasive ventilation, or intubation, or death.

Measure: Survival time without needs of a ventilator.

Time: Day 30

Secondary Outcomes

Description: The percentage of patients i) not hospitalized, without limitation of activities, ii) Not hospitalized, with activity limitation, iii) Hospitalized without oxygen therapy, iv) Hospitalized with oxygen therapy, v) Hospitalized with intensive oxygen therapy or non- invasive ventilation (NIV), vi) Hospitalized and intubated or on extracorporeal membrane oxygenation (ECMO), vii) Dead.

Measure: Morbidity

Time: Day 15

Description: Difference of the SOFA (Sequential Organ Failure Assessment) mean score per patient between the two groups.

Measure: Morbidity

Time: Day 30

Measure: Mortality

Time: Day 30

Measure: Length of stay

Time: Day 30

Description: Quantitative SARS-CoV2 PCR carried out on pharyngeal specimen.

Measure: Effect on viral pharyngeal specimen clearance

Time: At inclusion and Day 7

Description: Quantitative SARS-CoV2 PCR carried out on blood specimen.

Measure: Effect on viral blood specimen clearance

Time: At inclusion and Day 7

Description: Effects on biological hemostasis parameters disorders.

Measure: Effect on hemostasis disorders

Time: At inclusion, Day 1 and every 48 hours

Description: Anti-SARS-Cov2 immunoglobulin G/A level and anti-SARS-Cov2 neutralizing antibody levels.

Measure: Kinetics of appearance of neutralizing antibodies

Time: At inclusion, Day 7

Description: Evolution of biological endotheliopathy parameters

Measure: Transfusion endotheliopathy effect

Time: At inclusion, Day 1, Day 7

Description: Evaluation of biological dosages on inflammation effects

Measure: Transfusion biological Inflammation effect

Time: At inclusion, Day 1, Day 7

Description: Number of transfusion adverse events

Measure: Transfusion hemovigilance

Time: 30 days

Measure: Decrease in the consumption of antibiotics

Time: 30 days

No related HPO nodes (Using clinical trials)